To quote a 2014 paper by Lewellen and Resutek, "firms with higher accruals tend to be less profitable in the future". Over the twelve months to December 2024, Gilead Sciences recorded an accrual ...

FOSTER CITY, Calif., March 12, 2025--Gilead Sciences, Inc. (Nasdaq: GILD) today announced the presentation of late-breaking data and multiple oral presentations from its innovative HIV treatment ...

Our calculations are based on comprehensive, delayed quotes. Stocks: Real-time U.S. stock quotes reflect trades reported through Nasdaq only; comprehensive quotes and volume reflect trading in all ...

The latest analyst rating for Gilead Sciences (NASDAQ:GILD) was provided by Morgan Stanley, and Gilead Sciences maintained their overweight rating. The last upgrade for Gilead Sciences Inc ...

Co-founder Finny Kuruvilla manages the firm’s largest two funds — Eventide Gilead and Eventide Healthcare and Life Sciences — and remains the firm’s largest owner, though more than 20 of ...

Derived prices are not provided by exchanges. They are derived by market makers in CFD OTC market and hence prices may not be accurate and may differ from the actual market price, meaning prices ...

Gilead markets several single-tablet regimens for HIV, and its next-generation products with better long-term safety profiles, led by Biktarvy, are boosting the company's market share.

The Handmaid's Tale season 6 showrunner Yahlin Chang promises a "full-scale rebellion" that will change everything for both ...

The government has identified life sciences as one of the sectors with the highest potential for growth in the UK and plans to make it a key pillar of its upcoming industry strategy. The ...